Search

It is crucial for universities to recognize early signals of scientific convergence. Scientific convergence describes a dynamic pattern where the distance between different fields of knowledge shrinks over time. This knowledge space is beneficial to radical innovations and new promising research topics. Research in converging areas of knowledge can therefore allow universities to establish a leading position in the science community. The Q-AKTIV project develops a new approach on the basis of machine learning to identify scientific convergence at an early stage. In this work, we briefly present this approach and the first results of empirical validation. We discuss the benefits of an instrument building on our approach for the strategic management of universities and other research institutes.

Bridging application-oriented research and industry is a central goal of interdisciplinary projects. Research projects with high R&D performance drive the development of breakthrough technologies that enable radical innovations. Such research projects require successful knowledge application and[for full text, please go to the a.m. URL], The ABC Conference: Algae Bioactive Compounds – from research to innovation

Due to its numerous bibliometric entries of scholarly articles and connected information Wikidata can serve as an open and rich source for deep scientometrical analyses. However, there are currently certain limitations: While 31.5% of all Wikidata entries represent scientific articles, only 8.9% are entries describing a person and the number of entries researcher is accordingly even lower. Another issue is the frequent absence of established relations between the scholarly article item and the author item although the author is already listed in Wikidata. To fill this gap and to improve the content of Wikidata in general, we established a workflow for matching authors and scholarly publications by integrating data from the ORCID (Open Researcher and Contributor ID) database. By this approach we were able to extend Wikidata by more than 12k author-publication relations and the method can be transferred to other enrichments based on ORCID data. This is extension is beneficial for Wikidata users performing bibliometrical analyses or using such metadata for other purposes.

Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS). Methods: The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Cases with obstetric complaints related to antiphospholipid antibodies (aPL) who tested positive for aPL at least twice were included prospectively and retrospectively. The seven-year survey results are reported. Results: 1000 women with 3553 episodes were included of which 2553 were historical and 1000 were latest episodes. All cases fulfilled the Sydney classification criteria. According to the laboratory categories, 292 (29.2%) were in category I, 357 (35.7%) in Era, 224 (22.4%) in IIb and 127 (12.7%) in IIc. Miscarriages were the most prevalent clinical manifestation in 386 cases (38.6%). Moreover, the presence of early preeclampsia (PE) and early foetal growth restriction (FGR) appeared in 181 (18.1%) and 161 (16.1%), respectively. In this series, 448 (44.8%) women received the recommended OAPS treatment. Patients with recommended treatment had a good live-birth rate (85%), but worse results (72.4%) were obtained in patients with any treatment (low-dose aspirin (LDA) or low-molecular-weight heparin (LMWH) not on recommended schedule, while patients with no treatment showed a poor birth rate (49.6%). Conclusion: In this series, recurrent miscarriage is the most frequent poor outcome. To avoid false-negative diagnoses, all laboratory category subsets were needed. OAPS cases have very good foetal-maternal outcomes when treated. Results suggest that we were able to improve our clinical practice to offer better treatment and outcomes to OAPS patients.

To analyse the clinical features, laboratory data, foetal-maternal outcomes, and follow-up in a cohort of 247 women with obstetric antiphospholipid syndrome (OAPS).The European Registry on APS became a Registry within the framework of the European Forum on Antiphospholipid Antibody projects and placed on a website in June 2010. Cases with obstetric complaints related to aPL who tested positive for aPL prospectively and retrospectively were included. The three-year survey results are reported.338 women with 1253 pregnancy episodes were included; 915 were historical and 338 were latest episodes. All these women tested positive for aPL. 247 of the 338 fulfilled the Sydney criteria. According to the laboratory categories, 84/247 were in category I, 42 in IIa, 66 in IIb and 55 in IIc. Obstetric complications other than foetal losses, appeared in 129 cases (52.2%). 192 (77.7%) had a live birth and 55 (22.3%) did not. The latter group of only 38 cases (69%) received adequate treatment and 17 (31%) did not. 177/247 (72%) women were put on heparin plus LDA. Thrombosis appeared in two during pregnancy and in 14 during the puerperium. 7 (3%) women evolved to complete SLE.OAPS shows differential characteristics than classical APS. All laboratory test categories are needed to avoid false-negative diagnoses. In some cases, complement levels could act as a serological marker. OAPS has very good foetal-maternal outcomes when treated. Thrombosis and progression to SLE in mothers with OAPS are scarce compared with "classical APS", suggesting that they have different aPL-mediated pathogenic mechanisms.